HR
PMVP icon

Howe & Rusling’s PMV Pharmaceuticals PMVP Stock Holding History

Howe & Rusling’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-72
Closed -$1K – 840
2022
Q3 		$1K Buy
+72
New +$1.04K ﹤0.01% 995

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Howe & Rusling's PMVP Position: Q4 2022 in Review

Howe & Rusling sold out of PMV Pharmaceuticals (PMVP) in Q4 2022, closing a stake of 72 shares — an estimated $1K sold.

Howe & Rusling first reported a position in PMVP in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

  • Howe & Rusling reported no remaining PMV Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 72 PMV Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Howe & Rusling first reported a position in PMV Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Howe & Rusling's PMV Pharmaceuticals position peaked at $1K in Q3 2022.
  • 115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.